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Abstract
Background
Opportunistic cervical cancer screening can lead to suboptimal screening coverage. Cover-
age could be increased after a personalised invitation to the target population. We present a
community randomized intervention study with three strategies aiming to increase screening
coverage.
Methods
The CRICERVA study is a community-based clinical trial to improve coverage of population-
based screening in the Cerdanyola SAP area in Barcelona.A total of 32,858 women residing
in the study area, aged 30 to 70 years were evaluated. A total of 15,965 women were identi-
fied as having no registration of a cervical cytology in the last 3.5 years within the Public
Health data base system. Eligible women were assigned to one of four community random-
ized intervention groups (IGs): (1) (IG1 N = 4197) personalised invitation letter, (2) (IG2 N =
3601) personalised invitation letter + informative leaflet, (3) (IG3 N = 6088) personalised
invitation letter + informative leaflet + personalised phone call and (4) (Control N = 2079)
based on spontaneous demand of cervical cancer screening as officially recommended. To
evaluate screening coverage, we used heterogeneity tests to compare impact of the inter-
ventions and mixed logistic regression models to assess the age effect. We refer a “rescue”
visit as the screening visit resulting from the study invitation.
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Results
Among the 13,886 women in the IGs, 2,862 were evaluated as having an adequate screen-
ing history after the initial contact; 4,263 were lost to follow-up and 5,341 were identified as
having insufficient screening and thus being eligible for a rescue visit. All intervention strate-
gies significantly increased participation to screening compared to the control group. Cover-
age after the intervention reached 84.1% while the control group reached 64.8%. The final
impact of our study was an increase of 20% in the three IGs and of 9% in the control group
(p<0.001). Within the intervention arms, age was an important determinant of rescue visits
showing a statistical interaction with the coverage attained in the IGs. Within the intervention
groups, final screening coverage was significantly higher in IG3 (84.4%) (p<0.001). How-
ever, the differences were more substantial in the age groups 50–59 and those 60+. The
highest impact of the IG3 intervention was observed among women 60+ y.o with 32.0% of
them being rescued for screening. The lowest impact of the interventions was in younger
women.
Conclusions
The study confirms that using individual contact methods and assigning a fixed screening
date notably increases participation in screening. The response to the invitation is strongly
dependent on age.
Trial Registration
ClinicalTrials.gov NCT01373723
Introduction
Despite numerous recommendations calling for the implementation of organised cancer
screening programmes, cervical cancer screening remains opportunistic in many European
countries. In Spain, the age-standardized incidence rate of cervical cancer remains relatively
low compared to many European countries with an estimated rate around 7.8 per 105 women
for 2012 and a mortality rate of 2.1 per 105[1–3]. However, cervical cancer mortality rates have
stopped to decline in the last decade [4].
Screening is largely opportunistic and free of charge within the Spanish Public Health sys-
tem. In the autonomous region of Catalonia, several actions have been implemented since
2006 to increase coverage of select populations [5]. Analysis of the Catalonian data has revealed
poor regular attendance, of once screened women, and high prevalence of cervical lesions in
women high poor screening history [6–7]. Some studies from Spain have reported that
between 50–80% of women with invasive cervical cancer had not undergone cytology testing
during the 10 years prior to their cancer diagnosis [8–10]. Consequently, an improved screen-
ing coverage seems to be necessary to observe a reduction in the mortality attributable to cervi-
cal cancer. This is in line with European guidelines and other scientific societies including
Spanish and Catalan ones, recommend an organized approach of ‘call and recall’ of the target
population[1,11–14]. However, a recent report analyzing the situation of cervical cancer
screening in Europe identified a large number of countries lacking a standardized approach
for quality assurance, for monitoring or evaluation of the country based strategies to prevent
cervical cancer [2]. These data suggest the need to further advocate for organized screening
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and to investigate different approaches to facilitate the transition from opportunistic to orga-
nized screening.
In this report, we aimed to evaluate the overall impact of personalized invitations to attend
cervical cancer screening.
Methods
The CRICERVA study [15, 16] is a cluster randomised community-based clinical trial imple-
mented within the Cerdanyola Primary Health Care Service (SAP Cerdanyola). SAP Cerda-
nyola is a predefined geographical area located in the metropolitan belt of Barcelona, Spain
(S1 File Published protocol S2 File.- Study protocol Spanish, S3 File.- Study protocol English
translation, S4 File.- Consort Checklist). It is subdivided into five Basic Health Care Centers,
four of which were included in the CRICERVA study. The fifth one is an upper- class residen-
tial area, socially very distinctive from the other areas, and excluded in this study.
At the time of the study, SAP Cerdanyola covered a population of 120,293 individuals, of
which 72,036 were women and 32,858 were within the screening target ages 30–70. As part of
the National Health Service (NHS), residents in a given area have assigned a general practi-
tioner (GP) and a set of specialists including gynecologists. Above 95% of the population is
covered by the NHS and, within a 5 year interval, above 90% of the women have had a contact
with the assigned GP [6].
For the study purposes, eligibility included women whose GP was assigned to the Cerdanyola
SAP area, were resident in the area for more than 6 months and had no record of a cervical
cytology result in the medical registry of cervical cancer screening in the last 3.5 years” (Fig 1).
Fig 1. Study flow diagram.
doi:10.1371/journal.pone.0170371.g001
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Medical records were reviewed searching for the date of the last available cervical cytology result
and 15,965 women with no cervical cytology records were identified. At this point, the four
Basic Health Care Centers were cluster-randomized into the different intervention groups:
including: The Intervention Group 1 (IG1) including 4197 women that received a personalised
invitation letter, the Intervention Group 2 (IG2) including 3601 women that received a person-
alised invitation letter plus and informative leaflet, the Intervention Group 3 (IG3) including
6088 women that received a personalised invitation letter plus the informative leaflet and a per-
sonalised phone call three days before the appointment and finally a Control group including
2079 women in which no action was taken and whose screening was based on spontaneous
demand during the study period. Women in the IGs were invited to participate accordingly to
the study arm. Generally women contacted the Basic Health Care Centers by phone to confirm
or to cancel the proposed appointment. At the first verbal contact with the women, the adequacy
of the screening history was evaluated and if women referred to have a private gynecologist for
cervical cancer screening visits, the date of her last visit was noted and the appointment was can-
celled. Further, women were excluded for a screening visit if they were not residents in the area,
had undergone a hysterectomy, had a current history of cervical disease; were HIV positive, im-
munosuppressed or dead. A total of 1420 were excluded. About 2% of the letters were returned
for erroneous address. Women selected for screening were verbally informed about the screen-
ing procedures and the significance of the results. Women lost to follow up were phoned at least
3 times after the field work of the study had finished.
No changes in eligibility criteria were observed throughout the study.
Opportunistic cervical cancer screening visits in the control group were registered during
the study period for comparison with the IGs.
The record search of the patients was initiated in January 2011, women were contacted
when the ethical approval was granted (May 2011) and the study trial was registered (June
2011). Recruitment started in June 2011 and finished in December 2013.
Statistical Analysis
Population-based coverage was estimated at baseline and after the intervention. Baseline cov-
erage relates to a 3.5 year period. Final coverage computes the baseline screening estimated
through our records plus the screening referred to take place within the private sector plus the
screening obtained through the rescue visit. Coverage estimates were stratified by age and by
intervention group and. Overall coverage was calculated by age-weighted for each arm. Chi-
square tests were used to compare intervention and control groups in terms of participation.
Mixed logistic regression models were used to estimated how age impacted in the rescue
proportion with the intervention group as a random effect and the age as categorical fixed
effect This analysis was restricted to participants in the three intervention groups and exclud-
ing women who were screened in private system,. Interaction between age and intervention
group was assessed by comparing the model with and without the interaction term using the
log-likelihood ratio test.
The level of significance used was p0.05. Analyses were performed using SPSS for Win-
dows v. 20.0. and R (version 3.2.5) with the lme4 package [17].
Ethics Approval
Approval of this study was granted by the Ethics Committee of the IDIAP Jordi Gol. No writ-
ten signature was requested to participants as the study involved regular clinical practice. This
was approved by the Ethical Committee.
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After the study was completed, we proceeded to call women in the control group that had
not requested a screening visit during the study period and that were eligible for screening.
Through the text we refer to ‘rescued’ women those that had insufficient screening uptake
and that through our personalized contact accepted to undergo screening for cervical cancer.
Results
Table 1 summarizes the different components of coverage in the 26,744 women targeted in the
intervention groups(IGs) and 4,694 women in the control group (Table 1). All women in the
IGs received an invitation letter with a specific date of the visit.
Amon the IGs, 5,341(20.0%) women had the study criteria to undertake a rescue screening
visit. There was no difference in the percent recruitment of this group across IGs. Further,
2,862 (10.7%) women call us back or come to the health center referring to have had a regular
cytology within the private sector. These women were registered as having an adequate screen-
ing and no further action was taken with them. This was more commonly reported by target
women in IG3 (13.8%) than by those in IG1(9.1%) or IG2 (8.2%) (p value <0.001). Finally,
4,263 (15.9) women were lost to follow-up with no differences across the IGs (p = 0.58).
Within the control group, opportunistic screening was registered in 428 (9.1%) women during
the study period.
All intervention strategies significantly increased participation to screening compared to
the control group. Coverage after the intervention reached 84.1%, while coverage in the con-
trol group reached 64.8% (Table 1). The final impact of our study resulted in an increase of
20% from the rescue components in the three IGs and of 9% in the control group (p<0.001).
Within IGs, final screening coverage was significantly higher in IG3 (84.4%) (p<0.001) which
represented an overall age-adjusted increase of our coverage estimation of 37.3%.
The analysis was consistent in the crude approach and using the log-likelihood ratio test
comparing the null model (no variables) with the model including the intervention group
(p<0.001).
Within IGs, age was an important determinant of rescue visits showing a statistical interac-
tion with attained coverage. The comparison between the IGs and age in four categories model
Table 1. Cervical cancer screening coverage at baseline, those referring a private gynecologist and rescued coverage post intervention and final
population coverage attained by intervention groups and the control group at five and a half years*.
IG1 IG2 IG3 TOTAL IGs CONTROL
N % N % N % N % N %
TARGET POPULATION 8504 100 7842 100 10398 100 26744 100 4694 100
BASELINE COVERAGE 4771 56.1 4568 58.3 4939 47.5 14278 53.4 2615 55.7
STUDY TARGET POPULATION 4197 49.3 3601 45.9 6088 58.5 13886 51.9 2079 44.3
PRIVATE SCREENING 778 9.1 649 8.2 1435 13.8 2862 10.7 NK
RESCUED& 1578 18.6 1367 17.4 2396 23.0 5341 20.0 428 9.1
Increased coverage$ 27.8% 26.2% 37.3% 31.0% 9%
FINAL COVERAGE 7127 83.8 6584 84.0 8770 84.4 22481 84.1 3043 64.8
LOST TO FOLLOW UP 1377 16.1 1258 16.0 1628 15.7 4263 15.9 NK
P value heterogeneity test in final coverage & lost to follow up P = 0.5807 NA
P value heterogeneity test in rescue & target population P = 0.000 P = 0.000
NK = Unknown NA = Not applicable. All percentages are referred to the Target Population.
& = For control group attendance to screening was opportunistic.
$ = Weighted coverage by age structure of IGs.
*The table excludes 1420 women because of hysterectomy for benign reasons, changes of residence and death.
doi:10.1371/journal.pone.0170371.t001
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showed to be highly significant, as well as it was the interaction between age and IGs
(p<0.001). Thus, coverage in the IGs could be better interpreted by age strata as described in
Table 2. Although IG3 reached higher rescue estimates in all intervention groups, the differ-
ences were more substantial in the age groups 50–59 and those 60+. The highest impact of IG3
was observed among women 60+ y.o with 32.0% of the target population being rescued for
screening. The lowest impact of the interventions were observed in younger women with no
difference by IGs.
Discussion
To our knowledge, this is the first population-based randomized trial designed to increase cervi-
cal cancer screening coverage in Catalonia. The study confirmed that an active search for women
to undergo screening for cervical cancer considerably increased participation rates among all age
groups and particularly so among women over age 49. Coverage post-intervention was 34%
higher than that observed under strict opportunistic screening. This improvement was likely due
to the provision of better information regarding screening and the invitation to participate and
this had a relevant effect among the elder target women. No major absolute differences were
observed between interventions strategies used. The trial identified a substantial number of
women that had never had a screening test, adding additional value to the study intervention and
confirmed a proportion of women attending private practice.
A letter with a fixed appointment for the three study arms was set up across the intervention
arms following previous recommendations [13,14]. In addition, (a) information regarding cer-
vical cancer and cervical cancer screening and (b) a personalized telephone call were included
in the different arms. The coverage reached in these groups was compared to that of the con-
trol group in which the official recommendations were implemented. That is, women in the
control group were not called for a screening test. In all circumstances a negative cytology was
followed by a 3 year interval for the next cytology test.
In the IGs there was a substantial overall increase in cervical cytology coverage during the
study period. Coverage went from 53.4% at baseline to 84.1% at the end of the study. The
increase in coverage was of a similar magnitude in the three intervention study arms, although
the percentage increase was higher for IG3 with a slightly higher final coverage of 84.4% com-
pared to the overall estimate. These results are consistent with a previous study in Spain in
which interventions based on written or telephone briefing were effective to increase a two
year cytological coverage compared to the control group [15].
When we evaluated the changes in coverage by age groups we observed that women in the
age groups 50–59 and 60+ showed the largest net benefit with increased coverage values of
21.2% and 27.3% respectively. Contrary, the baseline coverage for women younger than 40
was slightly higher and had a higher reporting of screening in the private sector compared to
other age groups. This resulted in a statistically significant lower impact of the study invitation
among this age group (14.8%) compared to the remaining age groups in which the coverage
increased from 70.5% to 85.3% (p<0.001). This baseline higher screening coverage among the
youngest is likely to be explained by the higher contact with reproductive health care centers
and implying that women are more likely to be offered a screening test together with other
medical services related to contraception or reproduction. Although our control arm showed
poorer screening uptake compared to the IGs (84.1%) the final coverage was higher (64.8%)
than the average reported for Catalonia [16]. This can be explained by the fact that the four
areas included in the study from SAP Cerdanyola have traditionally shown to have a good con-
nection with the NHS. These areas are represent a metropolitan urban environment with high
predominance of working class, where half of the women have a primary school completed or
Increasing Cervical Cancer Screening Coverage
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less and show an almost universal use of the Public Health Services compared to other areas in
Catalonia [16].
The answer to the invitation letter overall was 59.1% which compared to other efforts to
contact non-attenders can be considered high [18]. Our data is in line with a study in Italy in
which 23–58% of the women first invited to participate in the screening, accept, while second
remainder for those lost-to follow up dropped substantially the acceptance with a response
rate for a cervical pap was 11% and was lower in the elderly population [19]. As we have noted
in the analysis of women aged 60 and older [15], the fact that the letters were signed by the
family physician and the coordinators of the BHCC, who are generally professionals known by
the target population added to the overall coordination of the activity and probably helped to
increase attendance as observed by others [18]. However, when women lost to follow-up were
contacted by phone at the end of the study only 22% could be contacted (Manuscript in prepa-
ration). Multiple strategies are now under evaluation to reach these hard to reach women
including self-sampling approaches that may increase substantially the rescue of an additional
proportion of women [19–23].
Quality of the available information is reported to be key in influencing better allocation of
resources and better participation in screening [2, 14,24]. Part of this work could be done
because of the availability of eCAP, which provides individual medical histories in an elec-
tronic format and gives information on all activities occurring at the primary health care level
and it can be linked to cytology records. eCAP is also continuously updated. However, eCAP
does not always include hospital data, death records or assistance outside the public health care
system. Thus, the fact that we interviewed all the women participating in the study allowed us to
remove those women that did not need or were not eligible for screening. We are now exploring
the possibility of improving some of the data query in eCAP so that it can be used as a tool in
the forthcoming recommendations for cervical cancer screening.
The study is subject to several limitations. The study aimed to reach all women at risk of
cervical cancer in the study population. However, 16% of the women could not be contacted as
they never responded to our letter or telephone call. We do not know the exact reasons for this
as only 2% of the letters were returned to us due to a faulty addresses Although we had a good
response to the first phone contact in the intervention group including a telephone call, IG 3,
some women reacted negatively against being contacted by phone due to the huge number of
calls that they receive, often from sales people. This should be considered if a telephone contact
is recommended in future strategies. Maybe there is a group of women that cannot understand
the purpose of our invitation or that they do not want to be told what to do in terms of health
issues. Further work is needed in this topic.
Further, women with no screening records were asked about regular screening outside the
NHS. We could not verify the records of those women referring attending regular screening in
a private practice.
The study is by design a cluster randomized trial that would require a full multilevel model
analysis. This could only be done within IGs controlling by the influence of age. For the whole
population we had only aggregated information.
Taking into account the limitations mentioned above, the study supports the recommenda-
tion that screening coverage can substantially be increased under an organized approached to
personally contact subjects at risk. Finally, in a concomitant cost-effectiveness analysis of the
three trial interventions IG1, IG2 and IG3, the most cost-efficient intervention to increase the
uptake of cervical screening across ages compared with the opportunistic approach was send-
ing an invitation letter (IG1), specially to women60 years. IG2 was more costly for the bene-
fits in coverage and IG3 although was the best in coverage was also the one that used more
economical resources [25] (S5 File.- Submitted related work).
Increasing Cervical Cancer Screening Coverage
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Conclusions
The study confirms that using individual contact methods and assigning a fixed screening date
notably increases participation in screening. The response to our invitation process was
strongly dependent on age. The findings from this study could be used to facilitate the imple-
mentation of effective population-based strategies toward the transition from opportunistic to
organised cervical cancer screening.
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